Biobank 3 Hoorn Diabetes Care System Cohort follow up 2023
Recruiting
- Conditions
- Diabetesinsulin insensitivity100184241004099810057166
- Registration Number
- NL-OMON53604
- Lead Sponsor
- Amsterdam UMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 2500
Inclusion Criteria
- All adult newly diagnosed patients with T2D in the Hoorn DCS, who have not
yet been asked to participate in research;
- All DCS participants with T2D who have previously provided informed consent
to be contacted for research.
Exclusion Criteria
• Unable to give written informed consent.
• Serious mental impairment i.e. preventing to understand the study protocol /
aim.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint are diabetes progression and incident diabetes<br /><br>complications, including microvascular complications (foot complications,<br /><br>retinopathy, nephropathy), macrovascular complications (cardiovascular disease,<br /><br>including myocardial infarction, angina pectoris, heart failure, stroke,<br /><br>transient ischaemic attack and peripheral arterial disease) as well as<br /><br>all-cause and cause-specific mortality. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints include diabetes progression measured as anthropometrics,<br /><br>metabolic status, prevalence and severity of non-alcoholic fatty liver disease<br /><br>(NAFLD), medication use, psychological complications and quality of life. </p><br>